Investigation of Anti-Liver Cancer Activity of the Herbal Drug FDY003 Using Network Pharmacology

Ho-Sung Lee,1,2 In-Hee Lee,1,2 Sang-In Park,3 Minho Jung,4 Seung Gu Yang,5 Tae-Wook Kwon,2 and Dae-Yeon Lee1,2

1 The Fore Research Institute, 33 Saemunan-ro 5ga-gil, Jongno-gu, Seoul 03170, Republic of Korea
2 Forest Hospital, 33 Saemunan-ro 5ga-gil, Jongno-gu, Seoul 03170, Republic of Korea
3 Forestheal Hospital, 173 Ogeum-ro, Songpa-gu, Seoul 05641, Republic of Korea
4 Forest Hospital, 129 Ogeum-ro, Songpa-gu, Seoul 05549, Republic of Korea
5 Forest Hospital, 67 Dolma-ro, Bundang-gu, Seongnam 13586, Republic of Korea

Correspondence should be addressed to Ho-Sung Lee; forehslee@gmail.com and Dae-Yeon Lee; foresthrnd@gmail.com

Received 11 April 2022; Accepted 10 August 2022; Published 9 September 2022

Copyright © 2022 Ho-Sung Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Globally, liver cancer (LC) is the sixth-most frequently occurring and the second-most fatal malignancy, responsible for 0.83 million deaths annually [1]. Molecular-targeted and immune checkpoint therapies serve as the main treatment strategies for LC in clinical settings [2]. However, such treatment options and their efficacy are largely restricted to a few patients, which emphasizes the need to design and develop effective therapeutics for LC treatment [2]. There is growing recognition of herbal drugs as potent therapeutics for LC treatment to augment treatment efficacy while minimizing the development of side effects caused by anticancer treatments in patients with LC [3–7].

FDY003 is an herbal drug composed of Cordyceps militaris (Cm), Artemisia capillaris Thunberg (AcT), and Lonicera japonica Thunberg (LjT). It has antiproliferative and proapoptotic activities in cancer cells [8–11]. These anticancer activities arise primarily from the functional regulation of many oncogenes, tumor suppressors, and their cancer-associated signaling cascades [8–11]. However, the anticancer activity of Fdy003 against LC and its mechanistic characteristics from an integrated systems view remain unclear.

Network pharmacology is a field that is efficient for dissecting synergistic mechanistic characteristics of herbal drugs based on their related pharmacological and biomedical data [12–19]. This strategy merges the herbal drug-
associated comprehensive information into networks that represent the interaction between herbal medicines, bioactive components, and therapeutically targeted genes and proteins [12–19]. Network pharmacology seeks the synergistic mechanisms of herbal drugs by assessing the functional, structural, and topological nature of their associated networks [12–19]. Based on the network pharmacology, we assessed the therapeutic role of FDY003 in LC and evaluated the underlying systematic mechanisms.

2. Materials and Methods

2.1. Cell Culture. The HepG2 human LC cell line was obtained from the Korean Cell Line Bank (Seoul, Korea) and cultured in Dulbecco's modified Eagle medium (WELGENE Inc., Gyeongsang, Korea) supplemented with antibiotics (penicillin-streptomycin) (Thermo Fisher Scientific, Inc., Waltham, MA, USA) and 10% fetal bovine serum (FBS) (WELGENE Inc.). The cells were grown in a humidified incubator at 37°C with 5% CO₂.

2.2. Herbal Drug Preparation. For the preparation of FDY003, dried raw AcT (150.0 g), LjT (150.0 g), and Cm (100.0 g) were obtained from Hanpure Pharmaceuticals (Pocheon, Korea), mixed, and ground. The herbal mixture was dispersed in 70% ethanol (500 mL) and subjected to a 3 h reflux extraction process at −80°C. After purifying the herbal extracts with 80% and 90% ethanol solutions successively, they were lyophilized at −80°C and the resulting 50.4 g of freeze-dried extracts were stored at −20°C. We used distilled water to dissolve the prepared FDY003 samples before further experiments.

2.3. Analysis of Cell Viability upon Drug Treatment. The viability of the drug-treated cells was analyzed by water-soluble tetrazolium salt (WST-1) experiments. Cells (1.0 × 10⁴) were seeded and cultured in 96-well plates and treated with FDY003, sorafenib (Sigma-Aldrich, St. Louis, MO, USA), or both for 72 h. Next, cells were incubated for 2 h with WST-1 solution (Daeil Lab Service Co. Ltd., Seoul, Korea) at 37°C and 5% CO₂. The cell viability was assessed by measuring the absorbance (450 nm) of the samples on an xMark microplate absorbance spectrophotometer (Bio-Rad, Hercules, CA, USA).

2.4. Screening for Bioactive Chemical Components. First, we investigated comprehensive herbal medicine-related databases (e.g., a bioinformatics analysis tool for the molecular mechanism of traditional Chinese medicine [20], an anticancer herbs database of systems pharmacology [21], and the traditional Chinese medicine systems pharmacology [22]) and acquired large-scale data for the chemical composition of FDY003. For these components, we used pharmacokinetic parameters, namely drug-likeness, Caco-2 permeability, and oral bioavailability, for the screening of the bioactive chemical components, as previously described [14, 22, 23]. Drug-likeness determines whether a given chemical component can adequately serve as a drug based on its molecular structure and physicochemical properties [22, 24]. A chemical component with a drug-likeness equal to or greater than 0.18 (the mean drug-likeness based on the currently available drugs) is considered to have adequate drug-like functions [22, 24]. The Caco-2 permeability determines whether a given chemical component has adequate intestinal absorption and permeability [22, 25–27]; a chemical component with Caco-2 permeability equal to or greater than −0.4 is considered to have adequate intestinal permeability and absorption activity [28, 29]. Oral bioavailability determines whether an orally administered chemical component has an adequate delivery rate to reach the target sites of drug action [22, 30]. A chemical component with an oral bioavailability equal to or more than 30% is considered to have adequate absorption in the human body [22, 30]. Thus, chemical components with drug-likeness ≥ 0.18, Caco-2 permeability ≥ −0.4, and oral bioavailability ≥ 30% [14, 22, 23] were considered bioactive.

2.5. Target Screening. To screen the targets of the identified bioactive chemical components of FDY003, we investigated their simplified molecular input line entry system notation using PubChem [28] and imported the information into the diverse tools and databases used to evaluate the molecular interactions between the chemical components and genes and proteins as follows: PharmMapper [29], Similarity Ensemble Approach [31], SwissTargetPrediction [32], and Search Tool for Interactions of Chemicals 5 [33]. Among the FDY003 targets, the genes and proteins significantly associated with the LC pathological mechanisms were examined using “liver cancer” and “hepatocellular carcinoma” as query keywords in the following tools and databases: Pharmacogenomics Knowledgebase [34], Online Mendelian Inheritance in Man [35], Human Genome Epidemiology Navigator [36], DisGeNET [37], Comparative Toxicogenomics Database [38], Therapeutic Target Database [39], GeneCards [40], and DrugBank [41].

2.6. Generation and Analysis of Herbal Drug-Associated Networks. Herbal drug-associated networks consist of nodes (which refer to the herbal components, chemical components, targeted genes and proteins, and pathways) and edges (which refer to the interactions among the network nodes) [42]. The node degree represents the number of edges for a given node [42]. The herbal component–chemical component–target (H-C-T) network uses herbal components, chemical components, and targeted genes and proteins of FDY003 as nodes and their molecular interactions and associations as the edges. The H-C-T-Pathway (H-C-T-P) network was created by linking the targets of the H-C-T network to their correspondingly enriched LC-related signaling cascades. The protein-protein interaction (PPI) network used FDY003 targets as nodes and their interaction information (interactions with high confidence obtained from STRING [43]) as edges. Network generation and analysis were performed using the Cytoscape tool [44].
2.7. Analysis of Correlation between the Survival of Patients with LC and the Expression Profiles of FDY003 Targets. The correlations between the survival of patients with LC and the expression profiles of LC-associated targets of FDY003 were analyzed using the Kaplan–Meier Plotter [45], a commonly used database for the survival analysis with large-scale gene expression profiles and survival information of patients with various cancer types obtained from The Cancer Genome Atlas (TCGA) [46], the Gene Expression Omnibus (GEO) [47], and the European Genome-phenome Archive (EGA) [48]. The survival analysis was performed using an auto-selected best cut-off and the results with \( p < 0.05 \) (log-rank test) were regarded to be statistically significant. The clinical information of the included patients for the survival analysis is provided in Supplementary Table S1.

2.8. Exploration of Functional Enrichment of FDY003 Targets. The Gene Ontology (GO) and pathway enrichment of FDY003 targets were analyzed using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) [49] and the Kyoto Encyclopedia of Genes and Genomes (KEGG) [50], respectively, and the results having \( p < 0.05 \) were regarded to be statistically significant.

2.9. Investigation of Binding Affinities between the Chemical Components and Targets of FDY003. To assess the binding affinities between the chemical components and corresponding targets of FDY003, we calculated the binding energies. First, we imported the molecular structures of the bioactive components of FDY003 (obtained from the RCSB Protein Data Bank [51]) and their targets (obtained from PubChem [28]) into AutoDock Vina [52] and calculated the resulting binding energies. As suggested earlier [53, 54], the binding affinities between the chemical components and targets were considered to be highly significant if their corresponding binding energies were \( \leq -5.0 \).

3. Results

3.1. Inhibitory Role of FDY003 in LC. To assess the action of FDY003 against LC, HepG2 human LC cells were treated with FDY003 and/or sorafenib (a first-line therapeutic agent for LC treatment [2]), and the effects of the treatment on the cells were monitored. FDY003 significantly reduced the viability of HepG2 cells; the viability of the cells was further inhibited upon treatment with a combination of the herbal drug and sorafenib (Supplementary Figures S1A and S1B). These observations suggest that FDY003 exhibits inhibitory and chemosensitizing effects on the LC cells.

3.2. Identification of Bioactive Components and Targets of FDY003. As previously described, we selected FDY003 constituents with Caco-2 permeability \( \geq -0.4 \), drug-likeness \( \geq 0.18 \), and oral bioavailability \( \geq 30\% \), and considered them as bioactive components (Supplementary Tables S2 and S3) [8, 14, 22, 23]. Several components having potent anticancer functions against LC were also included in the list of bioactive components, despite their failure to meet the inclusion criteria (Supplementary Tables S2 and S3). Using the databases for examining the molecular binding interactions between the chemical components and genes and proteins, a total of 379 targets were investigated. Among them, 91 were determined to be associated significantly with the LC pathological mechanisms based on previous cancer biology and oncological studies (Figure 1, and Supplementary Tables S4 and S5).

3.3. Network Analysis of Poly-Pharmacological Mechanisms Underlying FDY003 Effects in LC Treatment. For the network pharmacology analysis, first, we united the FDY003-associated data and knowledge into an H-C-T network (Figure 2, and Supplementary Table S4 and S5). Among the targets in this network, 20.1% (19 of 91 targets), 23.1% (21 of 91 targets), and 74.7% (68 of 91 targets) were linked to the chemical components kaempferol, luteolin, and quercetin, respectively (Figure 2 and Supplementary Table S4), which demonstrated their key roles in exerting anti-LC effects of FDY003. Moreover, 70.3% (64 of 91 targets) were linked to two or more chemical components (Figure 2), which indicated the synergistic poly-pharmacological nature of the herbal drug.

Analytical investigation of complex interactions among the therapeutic targets of a given drug is pivotal for understanding the underlying treatment mechanisms [55–59]. Thus, we constructed a PPI network consisting of large-scale interactions among the FDY003 targets to further dissect their pharmacological features (Figure 3). For analyzing the network topology of the PPI network, we identified the network hubs having a relatively large number of interacting partners as compared to the nonhubs; they had a high probability of being effective drug targets [60, 61]. As described previously, nodes with number of edges \( \geq 2 \times \) the average node degree were considered hubs [62, 63]. As a result, the identified hubs were AKT1, AR, EGFR, ESR1, JUN, PIK3R1, SRC, TP53, and VEGFA (Figure 3), which suggests that they were the primary nodes mediating the therapeutic roles of FDY003 in LC. Additionally, the expression status of these hubs could estimate the survival rate of patients with LC (Figure 4), which suggests their prognostic roles.

To understand the mechanisms of action of FDY003 in LC treatment, we evaluated the GO terms and pathways that were functionally enriched for the targets. The results showed that the FDY003 targets were functionally involved in the control of survival and proliferative behaviors, apoptosis, and cell cycle of LC cells (Supplementary Figure S2), which suggests the potential FDY003 mechanisms in the LC treatment. Additionally, FDY003 could target key signaling cascades connected to diverse LC pathological mechanisms (Figure 5 and Supplementary Figure S2) as analyzed by the KEGG pathway enrichment investigation, which demonstrated that these pathways were important mediators of the FDY003 drug activity against LC.
3.4. Assessing the Binding Affinities of Chemical Components of FDY003 and Their Targets. We performed a molecular docking study to assess the binding affinities and active binding sites between the chemical components of FDY003 and their targets. The resulting binding energies of the chemical component-target pairs were less than \(-5.0\) kcal/mol (Figure 6 and Supplementary Figure S3 and Supplementary Table S6), which indicated their high pharmacological binding potentials.

4. Discussion

Globally, LC is the sixth-most frequently occurring and the second-most fatal malignancy, responsible for 0.83 million deaths annually [1]. Although the application of herbal drugs in cancer therapies has increased, their anti-LC activity and relevant mechanisms have not been fully studied from a systems view [3–7]. To address these issues, we conducted a system-perspective network pharmacological investigation into the activity and mechanisms of action of the herbal drug, FDY003, for LC treatment. Treatment with FDY003 significantly reduced the viability of human LC cells and elevated their chemosensitivity. A total of 16 potential bioactive chemical components of FDY003 and corresponding 91 targets were identified for the pathological process of LC. The FDY003 targets were functionally involved in the regulating survival, proliferation, apoptosis, and cell cycle of LC cells. Additionally, we found that FDY003 may target key signaling cascades connected to the diverse LC pathological mechanisms, namely, phosphoinositide 3-kinase (PI3K)-Akt, focal adhesion, interleukin (IL)-17, forkhead box O (FoxO), mitogen-activated protein kinase (MAPK), and tumor necrosis factor (TNF) pathways. Overall, this study added to the integrative mechanistic insights into the anti-LC potential of FDY003.

The hub targets identified from the analysis of the FDY003-associated PPI network modulate crucial LC pathological mechanisms, and this targeting may result in effective therapeutic effects against LC. AKT1 is an important regulator of the tumorigenic processes, migration,
Figure 3: The protein-protein interaction network for liver cancer-associated targets of FDY003. Purple nodes, hubs.

Figure 4: Analysis of the survival probability of patients for corresponding liver cancer-associated targets of FDY003. The Kaplan–Meier curves for the survival of liver cancer patients are associated with the expression levels of the indicated targets.
spreading, therapeutic sensitivity, resistance, survival, and proliferation of LC cells, and is a promising theragnostic target [64–67]. AR expression and activity influence angiogenesis, stemness, invasion, angiogenesis, epithelial-mesenchymal transition (EMT), migration, and oncogenesis of LC cells, and it is a prognostic determinant and response marker for anticancer therapies [68–73]. EGFR is responsible for the modulation of proliferation, metastasis, migration, self-renewal potential, EMT, angiogenesis, anchorage-independent growth, invasion, and drug sensitivity of LC cells and tumors, and its expression and activity are implicated in the initiation, recurrence, progression, metastasis, and aggressiveness of LC in patients [74–83]. ESR1 is involved in the coordination of migration, angiogenesis, cancer stem-like properties, mobility, proliferation, and invasion of LC cells, and its genetic and expression status correlate with cancer susceptibility, tumor growth, metastasis, and prognosis of LC [84–89]. JUN is an oncogenic transcription factor that promotes tumor formation, chemoresistance, invasion, proliferation, migration, and metastasis, and serves as a marker for evaluating chemotherapeutic responses [90–92]. PIK3R1 is highly expressed and activated in LC cells and tumors, and it stimulates their migration, proliferation, invasion, and survival [93, 94]. Its elevated expression level is associated with poor prognostic outcomes [93, 94]. Src is highly expressed in LC cells and tumors, and its targeting can repress anoikis resistance, metastasis, treatment resistance, growth, stemness, invasion, tumorigenesis, migration, and mobility [95–101]. The expression and mutations of TP53 serve as biomarkers of prognosis, therapeutic response, aggressiveness, progression, and survival in LC [102–107]. VEGFA contributes to the malignant processes in LC by inducing angiogenesis, growth, invasion, prosurvival, metastasis, lymphangiogenesis, and migration of LC cells and tumors, and its expression and polymorphisms are related to the therapeutic responsiveness, prognosis, and cancer susceptibility of patients with LC [108–113].

FDY003 may pharmacologically intervene in various signaling cascades that are key factors in the LC pathophysiology as well as potent treatment targets. The chemokine pathway impacts the pathological processes of LC in various aspects, including inflammation, immune response, angiogenesis, metastasis, invasion, carcinogenesis, migration, EMT, tumorigenic potential, tumor microenvironment remodeling, and proliferation of LC cells and tumors [114–117]. Its activity is further associated with decreased survival and poor prognosis in patients with LC [114–117]. The abnormally controlled function of the erythroblastic leukemia viral oncogene homolog (ErbB), focal adhesion, hypoxia-inducible factor (HIF)-1, MAPK, p53, PI3K-Akt, and vascular endothelial growth factor (VEGF) pathways may contribute to the malignant tumorigenic and progressive processes in LC by inducing uncontrolled survival and proliferation, angiogenesis, EMT, invasion, migration, and metastasis of LC cells and tumors [118–121]. Thus, they can function as key therapeutic targets [118–121]. The estrogen pathway exerts a protective role against LC by inhibiting cancerous inflammation [122, 123]. The FoxO pathway is a tumor-suppressing cascade whose activation induces antiproliferation and apoptosis of LC cells and confers the pharmacological effects of anticancer therapeutics [124–127]. The inflammatory IL-17, TNF, and toll-like receptor pathways are responsible for the modulation of not only the protumorigenic inflammation but also the proliferation, invasion, metastasis, migration, immune microenvironment, and treatment sensitivity of LC cells and tumors [128–134]. Their activities correlate with poor prognostic outcomes in patients with LC [128–134]. The programmed death-ligand 1 (PD-1)/
programmed cell death-ligand 1 (PD-L1) pathway drives the immune escape of LC cells and tumors and is the major target of immune checkpoint therapies [135, 136]. The activity of the prolactin pathway is enhanced in LC tissues and is a marker for disease stage, survival, and progression of LC [137–140].

The herbal and bioactive components of FDY003 are known to function as anti-LC pharmacological agents. AcT represses survival, invasion, growth, angiogenesis, and migration of LC cells by blocking the PI3K/Akt and IL-6/signal transducer and activator of transcription (STAT) 3 pathways [141–144]. Cm exerts antisurvival, antigrowth, and antiangiogenic effects in LC cells [145, 146]. Cordycepin targets integrin, focal adhesion kinase (FAK), c-Jun N-terminal kinases (JNK), PI3K/Akt/mammalian target of rapamycin (mTOR), nuclear factor erythroid-2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1)/nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), IL-6, IL-1β, TNF-α, extracellular-signal-regulated kinase (ERK), Fas, B-cell lymphoma-2 (Bcl-2), caspase, and C-X-C motif chemokine receptor (CXCR) 4 cascades, thereby leading to the repression of angiogenesis, metastasis, EMT, proliferation, viability, and invasion of LC cells [147–153]. Eriodyctiol induces cell cycle arrest and apoptosis of LC cells by targeting the poly ADP-ribose polymerase (PARP), Bcl-2, and BCL2-associated X (Bax) signaling [154]. Isorhamnetin and β-sitosterol suppress the survival, viability, and proliferation

Figure 6: Analysis of binding affinities between the bioactive chemical components of FDY003 and their targets. (a) Kaempferol–AR (binding energy = −8.0 kcal/mol). (b) Kaempferol–EGFR (binding energy = −8.1 kcal/mol). (c) Kaempferol–ESR1 (binding energy = −8.6 kcal/mol).
of LC cells [155, 156]. Kaempferol enhances the efficacy of anticancer agents whilst reducing the proliferative, migratory, and invasive behaviors of LC cells by modulating PI3K/mTOR/matrix metalloproteinase (MMP), endoplasmic reticulum (ER) stress/CCAAT/enhancer binding protein (CHOP)/autophagy, 5′ adenosine monophosphate-activated protein kinase (AMPK), reactive oxygen species (ROS), and caspase pathways [157–161]. Luteolin induces autophagy, cell cycle arrest, growth suppression, chemosensitization, proapoptosis, anti-invasion, antimigration, antiadhesion, and antiangiogenesis effects on LC cells [162–170]. These pharmacological effects are conferred through cyclin, p53, JNK, death receptor, Akt/osteopontin, PARP, caspase, myeloid cell leukemia 1 (Mcl-1), X-linked inhibitor of apoptosis protein (XIAP), Beclin-1, Bcl-2, Bax, BH3 interacting domain death agonist (Bid), and the ER stress signaling pathways [162–170]. Quercetin represses chemoresistance, survival, growth, migration, and proliferation of LC cells by perturbing the activities of p53, B-cell lymphoma-extra-large (Bcl-xL), Janus kinase (JAK)/STAT, β-catenin, casein kinase (CK) 2α, Notch1, hedgehog, cyclin, PI3K/Akt, protein kinase C (PKC), cyclooxygenase-2 (COX-2), Bax, specificity protein 1 (SP1), and mitogen-activated protein kinase (MEK)/ERK pathways [171–180].

5. Conclusions

In conclusion, we performed a system-perspective network pharmacological investigation into the activity and mechanisms underlying the effects of the herbal drug, FDY003, for LC treatment. FDY003 could reduce the viability of human LC cells and elevate their chemosensitivity. A total of 16 potential bioactive chemical components of FDY003 that pharmacologically regulate diverse LC-related drug targets and signaling cascades were identified. Further studies should focus on enhancing the therapeutic potential of herbal drugs as efficacious clinical agents for anticancer treatment, including investigations into their mechanisms of action in the modulation of a variety of cancerous and protumorigenic phenotypes and therapeutic sensitivities.

Data Availability

All data generated or analyzed during this study are included in this published article and its supplementary materials file.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

Acknowledgments

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2021R1F1A1049472).

Supplementary Materials

Supplementary Figure S1. Pharmacological role of FDY003 on the viability of human liver cancer cells. Supplementary Figure S2. Gene ontology and pathway enrichment analysis for the liver cancer-related targets of FDY003. Supplementary Figure S3. Analysis of binding affinities between the bioactive chemical components of FDY003 and their targets. Supplementary Table S1. Clinical information of the included patients for the survival analysis. Supplementary Table S2. List of chemical components of FDY003. Supplementary Table S3. List of bioactive chemical components of FDY003. Supplementary Table S4. List of targets for active phytochemical ingredients of FDY003. Supplementary Table S5. List of the genes and proteins associated with the pathological mechanisms of liver cancer. Supplementary Table S6. Binding energies between the bioactive chemical components of FDY003 and their targets. (Supplementary Materials)

References

[1] H. Sung, J. Ferlay, R. L. Siegel et al., “Global cancer statistics 2020: GLOBCANC estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: A Cancer Journal for Clinicians, vol. 71, no. 3, pp. 209–249, 2021.

[2] Z. Liu, Y. Lin, J. Zhang et al., “Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma,” Journal of Experimental & Clinical Cancer Research, vol. 38, no. 1, p. 447, 2019.

[3] F. Chen, Z. Zhong, H. Y. Tan et al., “Uncovering the anticancer mechanisms of Chinese herbal medicine formulas: therapeutic alternatives for liver cancer,” Frontiers in Pharmacology, vol. 11, p. 293, 2020.

[4] W. C. Cho and H. Y. Chen, “Transcatheter arterial chemoembolization combined with or without Chinese herbal therapy for hepatocellular carcinoma: meta-analysis,” Expert Opinion on Investigational Drugs, vol. 18, no. 5, pp. 617–635, 2009.

[5] M. B. Meng, Q. L. Wen, Y. L. Cui, B. She, and R. M. Zhang, “Meta-analysis: traditional Chinese medicine for improving immune response in patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization,” Explore, vol. 7, no. 1, pp. 37–43, 2011.

[6] X. Shu, M. McCulloch, H. Xiao, M. Broffman, and J. Gao, “Chinese herbal medicine and chemotherapy in the treatment of hepatocellular carcinoma: a meta-analysis of randomized controlled trials,” Integrative Cancer Therapies, vol. 4, no. 3, pp. 219–229, 2005.

[7] Z. Yang, X. Liao, and Y. Lu, “Add-on therapy with traditional Chinese medicine improves outcomes and reduces adverse events in hepatocellular carcinoma: a meta-analysis of randomized controlled trials,” Evidence-Based Complementary and Alternative Medicine, vol. 2017, Article ID 3428253, 11 pages, 2017.

[8] H. S. Lee, I. H. Lee, K. Kang et al., “A network pharmacology study on the molecular mechanisms of FDY003 for breast cancer treatment,” Evidence-Based Complementary and Alternative Medicine, vol. 2021, Article ID 3919143, 18 pages, 2021.

[9] D. Y. Lee and I. H. Lee, “FDY003 inhibits colon cancer in a Colo205 xenograft mouse model by decreasing oxidative stress,” Pharmacognosy Magazine, vol. 15, no. 65, pp. 675–681, 2019.

[10] H.-S. Lee, I.-H. Lee, K. Kang et al., “Systems pharmacology study of the antitumor cancer mechanisms of FDY003,” Natural Product Communications, vol. 15, no. 12, 2020.
[11] H.-S. Lee, I.-H. Lee, K. Kang et al., “Network pharmacology-based dissection of the comprehensive molecular mechanisms of the herbal prescription FDY003 against estrogen receptor-positive breast cancer,” *Natural Product Communications*, vol. 16, no. 9, Article ID 1934578X2110443, 2021.

[12] P. Poornima, J. D. Kumar, Q. Zhao, M. Blunder, and T. Efferth, “Network pharmacology of cancer: understanding of complex interactome to the design of multi-target specific therapeutics from nature,” *Pharmacological Research*, vol. 111, pp. 290–302, 2016.

[13] W. Y. Lee, C. Y. Lee, Y. S. Kim, and C. E. Kim, “The methodological trends of traditional herbal medicine employing network pharmacology,” *Biomolecules*, vol. 9, no. 362, p. 8, 2019.

[14] H. S. Lee, I. H. Lee, S. I. Park, and D. Y. Lee, “Network pharmacology-based investigation of the system-level molecular mechanisms of the hematopoietic activity of samultang, a traditional Korean herbal formula,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2020, Article ID 9048089, 17 pages, 2020.

[15] R. He, S. Ou, S. Chen, and S. Ding, “Network pharmacology-based study on the molecular biological mechanism of action for compound kushen in injection in anti-cancer effect,” *Medical Science Monitor*, vol. 26, Article ID e918530, 2020.

[16] J. L. Mi, C. Liu, M. Xu, and R. S. Wang, “Network pharmacology to uncover the molecular mechanisms of action of LeiGongTeng for the treatment of nasopharyngeal carcinoma,” *Medical Science Monitor Basic Research*, vol. 26, Article ID e925341, 2020.

[17] Y. Wang, B. Dong, W. Xue et al., “Anticancer effect of radix astragali on cholangiocarcinoma in vitro and its mechanism via network pharmacology,” *Medical Science Monitor*, vol. 26, Article ID e921162, 2020.

[18] T. Xu, Q. Wang, and M. Liu, “A network pharmacology approach to explore the potential mechanisms of huangjin-baishao herb pair in treatment of cancer,” *Medical Science Monitor*, vol. 26, Article ID e923199, 2020.

[19] S. Q. Zhang, H. B. Xu, S. J. Zhang, and X. Y. Li, “Identiﬁcation of the active compounds and signiﬁcant pathways of Artemisia annua in the treatment of non-small cell lung carcinoma based on network pharmacology,” *Medical Science Monitor*, vol. 26, Article ID e923624, 2020.

[20] Z. Liu, F. Guo, Y. Wang et al., “BATMAN-TCM: a bioinformatics analysis tool for molecular mechanism of traditional Chinese medicine,” *Scientific Reports*, vol. 6, no. 1, p. 21146, 2016.

[21] W. Tao, B. Li, S. Gao et al., “CancerHSP: anticancer herbs database of systems pharmacology,” *Scientific Reports*, vol. 5, no. 1, p. 11481, 2015.

[22] J. Ru, P. Li, J. Wang et al., “TCMSP: a database of systems pharmacology for drug discovery from herbal medicines,” *Journal of Cheminformatics*, vol. 6, no. 1, p. 13, 2014.

[23] S. J. Yue, L. T. Xin, Y. C. Fan et al., “Herb pair Danggui-Honghua: mechanisms underlying blood stasis syndrome by system pharmacology approach,” *Scientific Reports*, vol. 7, no. 1, p. 40318, 2017.

[24] A. Y. Lee, W. Park, T. W. Kang, M. H. Cha, and J. M. Chun, “Network pharmacology-based prediction of active compounds and molecular targets in Yijin-Tang acting on hyperlipidaemia and atherosclerosis,” *Journal of Ethnopharmacology*, vol. 221, pp. 151–159, 2018.

[25] Y. Kono, A. Iwasaki, K. Matsuoka, and T. Fujita, “Effect of mechanical agitation on cationic liposome transport across an unstirred water layer in caco-2 cells,” *Biological & Pharmaceutical Bulletin*, vol. 39, no. 8, pp. 1293–1299, 2016.

[26] D. A. Volpe, “Variability in Caco-2 and MDCK cell-based intestinal permeability assays,” *Journal of Pharmaceutical Sciences*, vol. 97, no. 2, pp. 712–725, 2008.

[27] M. N. Garcia, C. Flowers, and J. D. Cook, “The Caco-2 cell culture system can be used as a model to study food iron availability,” *Journal of Nutrition*, vol. 126, no. 1, pp. 251–258, 1996.

[28] S. Kim, J. Chen, T. Cheng et al., “PubChem 2019 update: improved access to chemical data,” *Nucleic Acids Research*, vol. 47, no. D1, pp. D1102–D1109, 2019.

[29] X. Wang, Y. Shen, S. Wang et al., “PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database,” *Nucleic Acids Research*, vol. 45, pp. W356–W360, 2017.

[30] C. K. Wang and D. J. Craik, “Cyclic peptide oral bioavailability: lessons from the past,” *Biopolymers*, vol. 106, no. 6, pp. 901–909, 2016.

[31] M. J. Keiser, B. L. Roth, B. N. Armbruster, P. Ernsberger, J. J. Irwin, and B. K. Shoichet, “Relating protein pharmacology by ligand chemistry,” *Nature Biotechnology*, vol. 25, no. 2, pp. 197–206, 2007.

[32] A. Daina, O. Michielin, and V. Zoete, “SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules,” *Nucleic Acids Research*, vol. 47, no. W1, pp. W357–W364, 2019.

[33] D. Szklarczyk, A. Santos, C. von Mering, L. Jensen, P. Bork, and M. Kuhn, “STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data,” *Nucleic Acids Research*, vol. 44, no. D1, pp. D380–D384, 2016.

[34] M. Whirl-Carrillo, E. M. McDonagh, J. M. Hebert et al., “Pharmacogenomics knowledge for personalized medicine,” *Clinical Pharmacology & Therapeutics*, vol. 92, no. 4, pp. 414–417, 2012.

[35] J. S. Amberger, C. A. Bocchini, F. Schiettecatte, A. F. Scott, and A. Hamosh, “OMIM.org: online mendelian inheritance in man (OMIM(R)), an online catalog of human genes and genetic disorders,” *Nucleic Acids Research*, vol. 43, pp. D789–D798, 2015.

[36] W. Yu, M. Gwinn, M. Clyne, A. Yesupriya, and M. J. Khoury, “A navigator for human genome epidemiology,” *Nature Genetics*, vol. 40, no. 2, pp. 124-125, 2008.

[37] J. Pinerio, A. Bravo, N. Queralt-Rosinach et al., “DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants,” *Nucleic Acids Research*, vol. 45, no. D1, pp. D833–D839, 2017.

[38] A. P. Davis, C. J. Grondin, R. J. Johnson et al., “xQ_he comparative toxicogenomics database: update 2019,” *Nucleic Acids Research*, vol. 47, no. D1, pp. D948–D954, 2019.

[39] F. Zhu, B. Han, P. Kumari et al., “Update of TTD: therapeutic target database,” *Nucleic Acids Research*, vol. 38, no. suppl_1, pp. D787–D791, 2010.

[40] M. Safran, I. Dalah, J. Alexander et al., “GeneCards version 3: a comprehensive target pharmacophore database,” *Nucleic Acids Research*, vol. 38, no. D1, pp. D1074–D1082, 2010.
Evidence-Based Complementary and Alternative Medicine

[43] D. Szklarczyk, A. L. Gable, D. Lyon et al., “STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets,” Nucleic Acids Research, vol. 47, no. D1, pp. D607–D613, 2019.

[44] P. Shannon, A. Markiel, O. Ozier et al., “Cytoscape: a software environment for integrated models of biomolecular interaction networks,” Genome Research, vol. 13, no. 11, pp. 2498–2504, 2003.

[45] A. Nagy, A. Lanczyk, O. Menyhart, and B. Gyorffy, “Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets,” Scientific Reports, vol. 8, no. 1, p. 9227, 2018.

[46] J. N. Weinstein, E. A. Collisson, G. B. Mills et al., “The cancer genome Atlas pan-cancer analysis project,” Nature Genetics, vol. 45, no. 10, pp. 1113–1200, 2013.

[47] T. Barrett, S. E. Wilhite, P. Ledoux et al., “NCBI GEO: archive and analysis of functional genomics data sets–update,” Nucleic Acids Research, vol. 41, no. D1, pp. D991–D995, 2013.

[48] I. Lappalainen, I. Almeida-King, V. Kumanduri et al., “The European genome-phenome archive of human data consented for biomedical research,” Nature Genetics, vol. 47, no. 7, pp. 692–695, 2015.

[49] D. W. Huang, B. T. Sherman, and R. A. Lempicki, “Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources,” Nature Protocols, vol. 4, no. 1, pp. 44–57, 2009.

[50] M. Kanehisa, M. Furumichi, M. Tanabe, Y. Sato, and K. Morishima, “KEGG: new perspectives on genomes, pathways, diseases and drugs,” Nucleic Acids Research, vol. 45, no. D1, pp. D353–D361, 2017.

[51] S. K. Burley, H. M. Berman, C. Bhikadiya et al., “RCSP protein data bank: biological macromolecular structures enabling research and education in fundamental biology, biomedicine, biotechnology and energy,” Nucleic Acids Research, vol. 47, no. D1, pp. D464–D474, 2019.

[52] O. Trott and A. J. Olson, “AutoDock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading,” Journal of Computational Chemistry, vol. 31, no. 2, pp. 455–461, 2010.

[53] Z. Zhuang, J. Wen, L. Zhang et al., “Can network pharmacology identify the anti-virus and anti-inflammatory activities of Shuanghuanglian oral liquid used in Chinese medicine for respiratory tract infection?” European Journal of Integrative Medicine, vol. 37, Article ID 101139, 2020.

[54] M. Zhang, Y. Yuan, W. Zhou et al., “Network pharmacology analysis of Chaihu Lihzhong Tang treating non-alcoholic fatty liver disease,” Computational Biology and Chemistry, vol. 86, Article ID 107248, 2020.

[55] A. Athanasiou, V. Charalampos, T. Vasileios, and G. M. Ashraf, “Protein-protein interaction (PPI) network: recent advances in drug discovery,” Current Drug Metabolism, vol. 18, no. 1, pp. 5–10, 2017.

[56] L. H. Chu and B. S. Chen, “Construction of a cancer-perturbed protein-protein interaction network for discovery of apoptosis drug targets,” BMC Systems Biology, vol. 2, no. 1, p. 56, 2008.

[57] J. Huang, C. Niu, C. D. Green, L. Yang, H. Mei, and J. D. J. Han, “Systematic prediction of pharmacodynamic drug-drug interactions through protein-protein-interaction network,” PLoS Computational Biology, vol. 9, no. 3, Article ID e1002998, 2013.

[58] M. A. Yildirim, K. I. Goh, M. E. Cusick, A. L. Barabasi, and M. Vidal, “Drug-target network,” Nature Biotechnology, vol. 25, no. 10, pp. 1119–1126, 2007.
Evidence-Based Complementary and Alternative Medicine

signaling. “Cell Death & Differentiation,” vol. 27, no. 12, pp. 3258–3272, 2020.

[73] Y. Xiao, Y. Sun, G. Liu et al., “Androgen receptor (AR)/miR-520f-3p/ Sox9 signaling is involved in altering hepatocellular carcinoma (HCC) cell sensitivity to the sorafenib therapy under hypoxia via increasing cancer stem cells phenotype,” Cancer Letters, vol. 444, pp. 175–187, 2019.

[74] Z. Ezzoukhry, C. Louandre, E. Trecherel et al., “EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib,” International Journal of Cancer, vol. 131, no. 12, pp. 2961–2969, 2012.

[75] F. T. Fan, C. S. Shen, L. Tao et al., “PKM2 regulates hepatocarcinoma cell epithelial-mesenchymal transition and migration upon EGFR activation,” Asian Pacific Journal of Cancer Prevention, vol. 15, no. 5, pp. 1961–1970, 2014.

[76] L. Huang, C. Zhao, K. Sun et al., “Downregulation of CLDN6 inhibits cell proliferation, migration, and invasion via regulating EGFR/ AKT/mTOR signalling pathway in hepatocellular carcinoma,” Cell Biochemistry and Function, vol. 38, no. 5, pp. 541–548, 2020.

[77] J. W. Jang, Y. Song, S. H. Kim et al., “CD133 confers cancer stem-like cell properties by stabilizing EGFR-AKT signaling in hepatocarcinoma,” Cancer Letters, vol. 389, pp. 1–10, 2017.

[78] L. Kang, Z. H. Zhang, and Y. Zhao, “SCAMP3 is regulated by miR-128-3p and promotes the metastasis of hepatocellular carcinoma cells through EGFR-MAPK p38 signaling pathway,” American Journal of Translational Research, vol. 12, no. 12, pp. 7870–7884, 2020.

[79] C. Leng, Z. G. Zhang, W. X. Chen et al., “An integrin beta4-EGFR unit promotes hepatocarcinoma lung metastases by enhancing anchorage independence through activation of FAK-AKT pathway,” Cancer Letters, vol. 376, no. 1, pp. 188–196, 2016.

[80] R. Y. Wang, L. Chen, H. Y. Chen et al., “MUC15 inhibits dimerization of EGFR and PI3K-AKT signaling and is associated with aggressive hepatocellular carcinomas in patients,” Gastroenterology, vol. 145, no. 6, pp. 1436–1412, 2013.

[81] H. Xiao, R. Tong, C. Ding et al., “γ-H2AX promotes hepatocellular carcinoma angiogenesis via EGFR/HIF-1α/VEGF pathways under hypoxic condition,” Oncotarget, vol. 6, no. 4, pp. 2180–2192, 2015.

[82] D. Zhao, B. Zhai, and C. He, “Upregulation of HIF-2alpha induced by sorafenib contributes to the resistance by activating the TGFP-alpha/EGFR pathway in hepatocellular carcinoma cells,” Cellular Signalling, vol. 26, no. 5, pp. 1030–1039, 2014.

[83] Y. N. Zhao, J. Cao, and F. X. Wu, “Expression and significance of EGF mRNA and EGFR mRNA in hepatocellular carcinoma,” Ai Zheng, vol. 23, no. 7, pp. 762–766, 2004.

[84] M. Hishida, S. Nomoto, Y. Inokawa et al., “Estrogen receptor 1 gene as a tumor suppressor gene in hepatocellular carcinoma detected by triple-combination array analysis,” International Journal of Oncology, vol. 43, no. 1, pp. 88–94, 2013.

[85] J. Meng, L. Wang, J. Hou et al., “CCL23 suppresses liver cancer progression through the CCR1/AKT/ESR1 feedback loop,” Cancer Science, vol. 112, no. 8, pp. 3099–3110, 2021.

[86] M. L. Sheng, G. L. Xu, C. H. Zhang et al., “Aberrant estrogen receptor alpha expression correlates with hepatocellular carcinoma metastasis and its mechanisms,” Hepato-Gastroenterology, vol. 61, no. 129, pp. 146–150, 2014.

[87] L. Wang, M. Cui, D. Cheng et al., “miR-9-5p facilitates hepatocellular carcinoma cell proliferation, migration and invasion by targeting ESR1,” Molecular and Cellular Biochemistry, vol. 476, no. 2, pp. 575–583, 2021.

[88] Y. Wu, M. Zhang, X. Bi, L. Hao, R. Liu, and H. Zhang, “ESR1 mediated circ_0004018 suppresses angiogenesis in hepatocellular carcinoma via recruiting PUS and stabilizing TIP2 expression,” Experimental Cell Research, vol. 408, no. 2, 2021.

[89] Y. Zhai, G. Zhou, G. Deng et al., “Estrogen receptor alpha polymorphisms associated with susceptibility to hepatocellular carcinoma in hepatitis B virus carriers,” Gastroenterology, vol. 130, no. 7, pp. 2001–2009, 2006.

[90] W. Chen, W. Xiao, K. Zhang et al., “Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: preliminary clinical evidence,” Scientific Reports, vol. 6, no. 1, p. 22976, 2016.

[91] R. K. K. Chow, S. Tsz-Kwan Sin, M. Liu et al., “AKR7A3 suppresses tumorigenicity and chemoresistance in hepatocellular carcinoma through attenuation of ERK, c-Jun and NF-κB signaling pathways,” Oncotarget, vol. 8, no. 48, pp. 83469–83479, 2017.

[92] C. Liu, X. Peng, Y. Li et al., “Positive feedback loop of FAM83A/PI3K/AKT/c-Jun induces migration, invasion and metastasis in hepatocellular carcinoma,” Biomedicine & Pharmacotherapy, vol. 123, Article ID 109780, 2020.

[93] X. Ai, L. Xiang, Z. Huang et al., “Overexpression of PIK3R1 promotes hepatocellular carcinoma progression,” Biological Research, vol. 51, no. 1, pp. 52, 2018.

[94] S. He, J. Zhang, W. Zhang, F. Chen, and R. Luo, “FOXA1 inhibits hepatocellular carcinoma progression by suppressing PIK3R1 expression in male patients,” Journal of Experimental & Clinical Cancer Research, vol. 36, no. 1, p. 175, 2017.

[95] J. Bao, X. Chen, Y. Hou, G. Kang, Q. Li, and Y. Xu, “LncRNA DBH-AS1 facilitates the tumorigenesis of hepatocellular carcinoma by targeting miR-138 via FAK/Src/ERK pathway,” Biomedicine & Pharmacotherapy, vol. 107, pp. 824–833, 2018.

[96] Z. Dai, S. L. Zhou, Z. J. Zhou et al., “Capn4 contributes to tumour growth and metastasis of hepatocellular carcinoma by activation of the FAK-Src signalling pathways,” The Journal of Pathology, vol. 234, no. 3, pp. 316–328, 2014.

[97] W. C. Huang, S. L. Tung, Y. L. Chen, P. M. Chen, and P. Y. Chu, “IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway,” BMC Cancer, vol. 18, no. 1, p. 609, 2018.

[98] G. M. Lau, G. M. Lau, G. L. Yu et al., “Expression of Src and FAK in hepatocellular carcinoma and the effect of Src inhibitors on hepatocellular carcinoma in vitro,” Digestive Diseases and Sciences, vol. 54, no. 7, pp. 1465–1474, 2009.

[99] C. F. Mo, J. Li, S. X. Yang et al., “IQGAP1 promotes aneuploidy resistance and metastasis through Rac1-dependent ROS accumulation and activation of Src/FAK signalling in hepatocellular carcinoma,” British Journal of Cancer, vol. 123, no. 7, pp. 1154–1163, 2020.

[100] R. Zhao, L. Tan, Y. Zhang et al., “EF24 suppresses invasion and migration of hepatocellular carcinoma cells in vitro via inhibiting the phosphorylation of src,” BioMed Research International, vol. 2016, Article ID 8596984, 8 pages, 2016.

[101] R. Zhao, Y. Wu, T. Wang et al., “Elevated Src expression associated with hepatocellular carcinoma metastasis in northern Chinese patients,” Oncology Letters, vol. 10, no. 5, pp. 3026–3034, 2015.

[102] S. P. Hussain, J. Schwank, F. Staib, X. W. Wang, and C. C. Harris, “TP53 mutations and hepatocellular carcinoma:...
insights into the etiology and pathogenesis of liver cancer," *Oncogene*, vol. 26, no. 15, pp. 2166–2176, 2007.

[103] J. Long, A. Wang, Y. Bai et al., "Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma," *EBioMedicine*, vol. 42, pp. 363–374, 2019.

[104] H. G. Woo, X. W. Wang, A. Budhu et al., "Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma," *Gastroenterology*, vol. 140, no. 3, pp. 1063–1070, 2011.

[105] S. Ye, X. Y. Zhao, X. G. Hu et al., "TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma," *Oncology Reports*, vol. 37, no. 4, pp. 2215–2226, 2017.

[106] P. Zhan and Y. N. Ji, "Prognostic significance of TP53 expression for patients with hepatocellular carcinoma: a meta-analysis," *Hepatobiliary Surgery and Nutrition*, vol. 3, no. 1, pp. 11–17, 2014.

[107] P. Zhan, Y. N. Ji, and L. K. Yu, "TP53 mutation is associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a meta-analysis," *Hepatobiliary Surgery and Nutrition*, vol. 2, no. 5, pp. 260–265, 2013.

[108] A. Ghosh, D. Dasgupta, A. Ghosh et al., "MiRNA199a-3p suppresses tumor growth, migration, invasion and angiogenesis in hepatocellular carcinoma by targeting VEGFA, VEGFR1, VEGFR2, HGF and MMP2," *Cell Death & Disease*, vol. 8, no. 3, p. e2706, 2017.

[109] E. Horwitz, I. Stein, M. Andreozzi et al., "Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment," *Cancer Discovery*, vol. 4, no. 6, pp. 730–743, 2014.

[110] C. R. Oh, S. Y. Kong, H. S. Im et al., "Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with sorafenib," *BMC Cancer*, vol. 19, no. 1, p. 292, 2019.

[111] Y. Shi, X. Yang, X. Xue et al., "HANR promotes lymphangiogenesis of hepatocellular carcinoma via secreting miR-296 exosome and regulating EAG1/VEGFA signaling in HDLEC cells," *Journal of Cellular Biochemistry*, vol. 120, no. 10, pp. 17699–17708, 2019.

[112] X. Wu, Z. Xin, W. Zhang et al., "Polymorphisms in the VEGFA promoter are associated with susceptibility to hepatocellular carcinoma by altering promoter activity," *International Journal of Cancer*, vol. 133, no. 5, pp. 1085–1093, 2013.

[113] J. J. Yan, Y. N. Zhang, J. Z. Liao et al., "MiR-497 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting VEGFA and AEG-1," *Oncotarget*, vol. 6, no. 30, pp. 29527–29542, 2015.

[114] F. Huang and X. P. Geng, "Chemokines and hepatocellular carcinoma," *World Journal of Gastroenterology*, vol. 16, no. 15, pp. 1832–1836, 2010.

[115] C. M. Liang, L. Chen, and H. Hu, "Chemokines and their receptors play important roles in the development of hepatocellular carcinoma," *World Journal of Hepatology*, vol. 7, no. 10, pp. 1390–1402, 2015.

[116] X. Pan, A. C. Kaminga, S. W. Wen, and A. Liu, "Chemokines in hepatocellular carcinoma: a meta-analysis," *Carcinogenesis*, vol. 41, no. 12, pp. 1682–1694, 2020.

[117] D. Xue, Y. Zheng, J. Wen et al., "Role of chemokines in hepatocellular carcinoma (review)," *Oncology Reports*, vol. 45, no. 3, pp. 809–823, 2021.

[118] S. M. Akula, S. L. Abrams, L. S. Steelman et al., "RAS/RAF/MEK/ERK, PI3K/PTEN/PI3K/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma," *Expert Opinion on Therapeutic Targets*, vol. 23, no. 11, pp. 915–929, 2019.

[119] C. Chen and T. Lou, "Hypoxia inducible factors in hepatocellular carcinoma," *Oncotarget*, vol. 8, no. 28, pp. 46691–46703, 2017.

[120] Y. Guo, Z. Xiao, L. Yang et al., "Hypoxia-inducible factors in hepatocellular carcinoma (review)," *Oncology Reports*, vol. 43, no. 1, pp. 3–15, 2020.

[121] X. Meng, D. A. Franklin, J. Dong, and Y. Zhang, "MDM2-p53 pathway in hepatocellular carcinoma," *Cancer Research*, vol. 74, no. 24, pp. 7161–7167, 2014.

[122] L. Shi, Y. Feng, H. Lin, R. Ma, and X. Cai, "Role of estrogen in hepatocellular carcinoma: is inflammation the key?" *Journal of Translational Medicine*, vol. 12, no. 1, p. 93, 2014.

[123] O. A. Sukhocheva, "Estrogen, estrogen receptors, and hepatocellular carcinoma: are we there yet?" *World Journal of Gastroenterology*, vol. 24, no. 1, pp. 1–4, 2018.

[124] M. Abd-Elhase, A. M. Mansour, O. M. Ahmed, and A. M. Abou-Youssef, "The potential chemotherapeutic effect of beta-ionone and/or sorafenib against hepatocellular carcinoma via its antioxidant effect, PPAR-gamma, FOXO-1, Ki-67, Bax, and Bcl-2 signaling pathways," *Naunyn Schmiedeberg’s Archives of Pharmacology*, vol. 393, no. 9, pp. 1611–1624, 2020.

[125] Y. Li, P. Li, and N. Wang, "Effect of let-7c on the PI3K/Akt/FoxO signaling pathway in hepatocellular carcinoma," *Oncology Letters*, vol. 21, no. 2, p. 96, 2021.

[126] K. Lou, N. Chen, Z. Li et al., "MicroRNA-142-5p overexpression inhibits cell growth and induces apoptosis by regulating FOXO in hepatocellular carcinoma cells," *Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics*, vol. 25, no. 1, pp. 65–73, 2017.

[127] F. Yamaguchi, Y. Hirata, H. Akram et al., "FOXO/TXNIP pathway is involved in the suppression of hepatocellular carcinoma growth by glutamate antagonist MK-801," *BMC Cancer*, vol. 13, no. 1, p. 468, 2013.

[128] V. Kairaluoma, N. Kemi, H. Huhta, V. M. Pohjanen, and O. Helminen, "Toll-like receptor 5 and 8 in hepatocellular carcinoma," *Acta Pathologica, Microbiologica et Immunologica Scandinavica*, vol. 129, no. 8, pp. 470–479, 2021.

[129] Z. Sepehri, Z. Kiani, F. Kohan, S. M. Alavian, and S. Ghavami, "Toll-like receptor 4 and hepatocellular carcinoma: A systematic review," *Life Sciences*, vol. 179, pp. 80–87, 2017.

[130] S. N. Wang, S. T. Wang, and K. T. Lee, "The potential interplay of adipokines with toll-like receptors in the development of hepatocellular carcinoma," *Gastroenterol Res Pract*, vol. 2011, Article ID 215986, 2011.

[131] R. Bansal, "Battling IL-17, the troublemaker in alcohol-induced hepatocellular carcinoma," *Journal of Hepatology*, vol. 72, no. 5, pp. 809–812, 2020.

[132] R. Liao, J. Sun, H. Wu et al., "High expression of IL-17 and IL-17RE associate with poor prognosis of hepatocellular carcinoma," *Journal of Experimental & Clinical Cancer Research*, vol. 32, no. 1, p. 3, 2013.

[133] O. Hammam, O. Mahmoud, M. Zahran et al., "A possible role for TNF-alpha in coordinating inflammation and angiogenesis in chronic liver disease and hepatocellular carcinoma," *Gastrointestinal Cancer Research*, vol. 6, no. 4, pp. 107–114, 2013.
Evidence-Based Complementary and Alternative Medicine

[134] W. Tan, X. Luo, W. Li et al., "TNF-alpha is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma," *Ebiomedicine*, vol. 40, pp. 446–456, 2019.

[135] A. D’Alessio, L. Rimassa, A. Cortellini, and D. J. Pinato, "PD-1 blockade for hepatocellular carcinoma: current research and future prospects," *Journal of Hepatocellular Carcinoma*, vol. 8, pp. 887–907, 2021.

[136] D. J. Pinato, N. Guerra, P. Fessas et al., "Immune-based therapies for hepatocellular carcinoma," *Oncogene*, vol. 39, no. 18, pp. 3620–3637, 2020.

[137] T. Garcia-Caballero, H. M. Mertani, A. Lambert et al., "Increased expression of growth hormone and prolactin receptors in hepatocellular carcinomas," *Endocrine*, vol. 12, no. 3, pp. 265–272, 2000.

[138] X. Kong, W. Wu, Y. Yuan et al., "Human growth hormone and human prolactin function as autocrine/paracrine promoters of progression of hepatocellular carcinoma," *Onco-target*, vol. 7, no. 20, pp. 29465–29479, 2016.

[139] W. W. Wang, S. F. Ang, R. Kumar et al., "Identification of serum monocyte chemoattractant protein-1 and prolactin as potential tumor markers in hepatocellular carcinoma," *PLoS One*, vol. 8, no. 7, Article ID e68904, 2013.

[140] Y. T. Yeh, K. T. Lee, C. J. Tsai, Y. J. Chen, and S. N. Wang, "Prolactin promotes hepatocellular carcinoma through Janus kinase 2," *World Journal of Surgery*, vol. 36, no. 5, pp. 1128–1135, 2012.

[141] E. Jang, S. Y. Kim, N. R. Lee et al., "Evaluation of antitumor activity of Artemisia capillaris extract against hepatocellular carcinoma through the inhibition of IL-6/STAT3 signaling axis," *Oncology Reports*, vol. 37, no. 1, pp. 526–532, 2017.

[142] K. H. Jung, M. Rumman, H. Yan et al., "An ethyl acetate fraction of Artemisia capillaris (ACE-63) induced apoptosis and anti-angiogenesis via inhibition of PI3K/AKT signaling in hepatocellular carcinoma," *Phytotherapy Research*, vol. 32, no. 10, pp. 2034–2046, 2018.

[143] J. Kim, K. H. Jung, H. H. Yan et al., "Artemisia capillaris leaves inhibit cell proliferation and induce apoptosis in hepatocellular carcinoma," *BMC Complementary and Alternative Medicine*, vol. 18, no. 1, p. 147, 2018.

[144] H. Yan, K. H. Jung, J. Kim, M. Rumman, M. S. Oh, and S. S. Hong, "Artemisia capillaris extract AC68 induces apoptosis of hepatocellular carcinoma by blocking the PI3K/ AKT pathway," *Biomedicine & Pharmacotherapy*, vol. 98, pp. 134–141, 2018.

[145] K.-M. Kim, C. Park, Y.-H. Choi, and W.-H. Lee, "Induction of apoptosis by water extract of Cordyceps militaris (WECM) in human hepatocellular carcinoma HepG2 cells," *Journal of Life Sciences*, vol. 18, no. 6, pp. 804–813, 2008.

[146] Z. Li, Z. Guo, and J. Zhu, "Cordyceps militaris fraction inhibits angiogenesis of hepatocellular carcinoma in vitro and in vivo," *Pharmaceutical Magazine*, vol. 16, no. 67, p. 169, 2020.

[147] Z. Guo, W. Chen, G. Dai, and Y. Huang, "Cordycepin suppresses the migration and invasion of human liver cancer cells by downregulating the expression of CXCR4," *International Journal of Molecular Medicine*, vol. 45, no. 1, pp. 141–150, 2020.

[148] H. H. Lee, J. W. Jeong, J. H. Lee et al., "Cordycepin increases sensitivity of Hep3B human hepatocellular carcinoma cells to TRAIL-mediated apoptosis by inactivating the JNK signaling pathway," *Oncology Reports*, vol. 30, no. 3, pp. 1257–1264, 2013.

[149] H. Lu, X. Li, J. Zhang, H. Shi, X. Zhu, and X. He, "Effects of cordycepin on HepG2 and EA.hy926 cells: potential anti-proliferative, antitumor and anti-angiogenic effects on hepatocellular carcinoma," *Oncology Letters*, vol. 7, no. 5, pp. 1556–1562, 2014.

[150] L. W. Shao, L. H. Huang, S. Yan, J. D. Jin, and S. Y. Ren, "Cordycepin induces apoptosis in human liver cancer HepG2 cells through extrinsic and intrinsic signaling pathways," *Oncology Letters*, vol. 12, no. 2, pp. 995–1000, 2016.

[151] W. L. Yao, B. S. Ko, T. A. Liu et al., "Cordycepin suppresses integrin/FAK signaling and epithelial-mesenchymal transition in hepatocellular carcinoma," *Anti-Cancer Agents in Medicinal Chemistry*, vol. 14, no. 1, pp. 29–34, 2014.

[152] Y. Zeng, S. Lian, and D. Li, "Anti-hepatocarcinoma effect of cordycepin against NDEA-induced hepatocellular carcinomas via the PI3K/Akt/mTOR and Nrf2/HO-1/NF-kappaB pathway in mice," *Biomedicine & Pharmacotherapy*, vol. 95, pp. 1868–1875, 2017.

[153] Y. Zhou, Z. Guo, Q. Meng et al., "Cordycepin affects multiple apoptotic pathways to mediate hepatocellular carcinoma cell death," *Anti-Cancer Agents in Medicinal Chemistry*, vol. 17, no. 1, pp. 143–149, 2017.

[154] F. Wang, Y.-H. Wang, J.-J. Wang, H.-L. Xu, and C.-M. Wang, "Eriodictyol-induced anti-cancer and apoptotic effects in human hepatocellular carcinoma cells are associated with cell cycle arrest and modulation of apoptosis-related proteins," *Bangladesh Journal of Pharmacology*, vol. 11, no. 2, pp. 285–291, 2016.

[155] R. Fei and H. Wei, "Quantitative proteomic analysis of Isorhamnetin treatment in human liver cancer cells," *Journal of Medicinal Plants Research*, vol. 12, no. 7, pp. 77–88, 2018.

[156] T. K. Vo, Q. T. H. Ta, Q. T. Chu, T. T. Nguyen, and V. G. Vo, "Anti-hepatocellular-cancer activity exerted by beta-sitosterol and beta-sitosterol-glucoside from Indigofera zollingeriana miq.," *Molecules*, vol. 25, no. 3021, p. 13, 2020.

[157] H. Guo, W. Lin, X. Zhang et al., "Kaempferol induces hepatocellular carcinoma cell death via endoplasmic reticulum stress-CHOP-autophagy signaling pathway," *Onco-target*, vol. 8, no. 47, pp. 82207–82216, 2017.

[158] B. Han, Y. Q. Yu, Q. L. Yang, C. Y. Shen, and X. J. Wang, "Kaempferol induces autophagic cell death of hepatocellular carcinoma cells via activating AMPK signaling," *Onco-target*, vol. 8, no. 49, pp. 86227–86239, 2017.

[159] B. Nair, R. J. Anto, and L. R. Nath, "Kaempferol-Mediated sensitization enhances chemotherapeutic efficacy of sorafenib against hepatocellular carcinoma: an in silico and in vitro approach," *Advanced Pharmaceutical Bulletin*, vol. 10, no. 3, pp. 472–476, 2020.

[160] E. Seydi, A. Salimi, H. R. Rasekh, Z. Mohsenifar, and J. Pourahmad, "Selective cytotoxicity of luteolin and kaempferol on cancerous hepatocytes obtained from rat model of hepatocellular carcinoma: involvement of ROS-mediated mitochondrial targeting," *Nutrition and Cancer*, vol. 70, no. 4, pp. 594–604, 2018.

[161] G. Yang, J. Xing, B. Aikemu, J. Sun, and M. Zheng, "Kaempferol exhibits a synergistic effect with doxorubicin to inhibit proliferation, migration, and invasion of liver cancer," *Oncology Reports*, vol. 45, no. 32, p. 4, 2021.

[162] Z. Cao, H. Zhang, X. Cai et al., "Luteolin promotes cell apoptosis by inducing autophagy in hepatocellular carcinoma," *Cellular Physiology and Biochemistry*, vol. 43, no. 5, pp. 1803–1812, 2017.

[163] X. Q. Feng, L. W. Rong, R. X. Wang et al., "Luteolin and sorafenib combination kills human hepatocellular carcinoma cells through apoptosis potentiation and JNK activation," *Oncology Letters*, vol. 16, no. 1, pp. 648–653, 2018.
[164] E. Im, C. Yeo, and E. O. Lee, "Luteolin induces caspase-dependent apoptosis via inhibiting the AKT/osteopontin pathway in human hepatocellular carcinoma SK-Hep-1 cells," *Life Sciences*, vol. 209, pp. 259–266, 2018.

[165] Y. Lee and Y. H. Kwon, "Regulation of apoptosis and autophagy by luteolin in human hepatocellular cancer Hep3B cells," *Biochemical and Biophysical Research Communications*, vol. 517, no. 4, pp. 617–622, 2019.

[166] U. M. Nazim and S. Y. Park, "Luteolin sensitizes human liver cancer cells to TRAIL-induced apoptosis via autophagy and JNK-mediated death receptor 5 upregulation," *International Journal of Oncology*, vol. 54, no. 2, pp. 665–672, 2019.

[167] H. Xu, T. Yang, X. Liu et al., "Luteolin synergizes the antitumor effects of 5-fluorouracil against human hepatocellular carcinoma cells through apoptosis induction and metabolism," *Life Sciences*, vol. 144, pp. 138–147, 2016.

[168] Y. Su Bog, L. Jung Hwa, C. Hae Young et al., "Inhibitory effects of luteolin isolated from Ixeris sonchifolia hance on the proliferation of HepG2 human hepatocellular carcinoma cells," *Archives of Pharmacal Research*, vol. 26, no. 2, pp. 151–156, 2003.

[169] X. Meng, W.-Q. Zhong, and X.-R. Zhang, "Effect of luteolin on HepG2 liver cancer cell proliferation in vitro and angiogenesis activity," *Journal of Hainan Medical University*, vol. 23, no. 23, pp. 9–12, 2017.

[170] Q. Wang, S. Shen, and X. G. Li, "Effects of luteolin on invasion, migration and adhesion of human hepatocellular carcinoma HepG2 cells," *Chinese Journal of Pathophysiology*, vol. 33, no. 9, pp. 1606–1610, 2017.

[171] Z. Chen, C. Huang, T. Ma et al., "Reversal effect of quercetin on multidrug resistance via FZD7/β-catenin pathway in hepatocellular carcinoma cells," *Phytotherapy Research*, vol. 43, pp. 37–45, 2018.

[172] Y. Ding, X. Chen, B. Wang, B. Yu, J. Ge, and X. Shi, "Quercetin suppresses the chymotrypsin-like activity of proteasome via inhibition of MEK1/ERK1/2 signaling pathway in hepatocellular carcinoma HepG2 cells," *Canadian Journal of Physiology and Pharmacology*, vol. 96, no. 5, pp. 521–526, 2018.

[173] I. Igbe, X. F. Shen, W. Jiao et al., "Dietary quercetin potentiates the antiproliferative effect of interferon-alpha in hepatocellular carcinoma cells through activation of JAK/STAT pathway signaling by inhibition of SHP2 phosphatase," *Oncotarget*, vol. 8, no. 69, pp. 113734–113748, 2017.

[174] Y. Ji, L. Li, Y. X. Ma et al., "Quercetin inhibits growth of hepatocellular carcinoma by apoptosis induction in part via autophagy stimulation in mice," *The Journal of Nutritional Biochemistry*, vol. 69, pp. 108–119, 2019.

[175] R. H. Lee, J. H. Cho, Y. J. Jeon et al., "Quercetin induces antiproliferative activity against human hepatocellular carcinoma (HepG2) cells by suppressing specificity protein 1 (Sp1)," *Drug Development Research*, vol. 76, no. 1, pp. 9–16, 2015.

[176] A. K. Maurya and M. Vinayak, "Anticarcinogenic action of quercetin by downregulation of phosphatidylinositol 3-kinase (PI3K) and protein kinase C (PKC) via induction of p53 in hepatocellular carcinoma (HepG2) cell line," *Molecular Biology Reports*, vol. 42, no. 9, pp. 1419–1429, 2015.

[177] Y. A. Salama, A. El-Karef, A. M. El Gayyar, and N. Abdel-Rahman, "Beyond its antioxidant properties: quercetin targets multiple signalling pathways in hepatocellular carcinoma in rats," *Life Sciences*, vol. 236, Article ID 116933, 2019.

[178] G. Wang, J. Zhang, L. Liu, S. Sharma, and Q. Dong, "Quercetin potentiates doxorubicin mediated antitumor effects against liver cancer through p53/Bcl-xL," *PLOS One*, vol. 7, no. 12, Article ID e51764, 2012.

[179] L. Wu, J. Li, T. Liu et al., "Quercetin shows anti-tumor effect in hepatocellular carcinoma LM3 cells by abrogating JAK2/STAT3 signaling pathway," *Cancer Medicine*, vol. 8, no. 10, pp. 4806–4820, 2019.

[180] N. Yamada, R. Matsushima-Nishiwaki, and O. Kozawa, "Quercetin suppresses the migration of hepatocellular carcinoma cells stimulated by hepatocyte growth factor or transforming growth factor-α: attenuation of AKT signaling pathway," *Archives of Biochemistry and Biophysics*, vol. 682, Article ID 108296, 2020.